117 related articles for article (PubMed ID: 7714713)
1. Fenbufen pretreatment potentiates the anticonvulsant activity of CPPene and NBQX in DBA/2 mice.
De Sarro G; Renne S; Nava F; De Sarro A
J Pharm Pharmacol; 1994 Dec; 46(12):1017-22. PubMed ID: 7714713
[TBL] [Abstract][Full Text] [Related]
2. Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX).
Swedberg MD; Jacobsen P; Honoré T
J Pharmacol Exp Ther; 1995 Sep; 274(3):1113-21. PubMed ID: 7562477
[TBL] [Abstract][Full Text] [Related]
3. Repeated treatment with adenosine A1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene.
De Sarro G; Donato Di Paola E; Falconi U; Ferreri G; De Sarro A
Eur J Pharmacol; 1996 Dec; 317(2-3):239-45. PubMed ID: 8997606
[TBL] [Abstract][Full Text] [Related]
4. Effects of some excitatory amino acid antagonists on imipenem-induced seizures in DBA/2 mice.
De Sarro G; Ammendola D; Nava F; De Sarro A
Brain Res; 1995 Feb; 671(1):131-40. PubMed ID: 7728525
[TBL] [Abstract][Full Text] [Related]
5. Aniracetam reverses the anticonvulsant action of NBQX and GYKI 52466 in DBA/2 mice.
Chapman AG; al-Zubaidy Z; Meldrum BS
Eur J Pharmacol; 1993 Feb; 231(2):301-3. PubMed ID: 8453982
[TBL] [Abstract][Full Text] [Related]
6. Anticonvulsant activity of 5,7DCKA, NBQX, and felbamate against some chemoconvulsants in DBA/2 mice.
De Sarro G; Ongini E; Bertorelli R; Aguglia U; De Sarro A
Pharmacol Biochem Behav; 1996 Oct; 55(2):281-7. PubMed ID: 8951966
[TBL] [Abstract][Full Text] [Related]
7. Probenecid pretreatment enhances anticonvulsant action of NBQX in mice.
Taylor CP; Vartanian MG
Eur J Pharmacol; 1992 Mar; 213(1):151-3. PubMed ID: 1499653
[TBL] [Abstract][Full Text] [Related]
8. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice.
Chapman AG; Smith SE; Meldrum BS
Epilepsy Res; 1991 Jul; 9(2):92-6. PubMed ID: 1794356
[TBL] [Abstract][Full Text] [Related]
9. N6-cyclohexyladenosine and 3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid enhance the effect of antiepileptic drugs against induced seizures in mice.
Assi AA
J Pharm Pharm Sci; 2001; 4(1):42-51. PubMed ID: 11302789
[TBL] [Abstract][Full Text] [Related]
10. Anticonvulsant properties of non-competitive antagonists of the N-methyl-D-aspartate receptor in genetically epilepsy-prone rats: comparison with CPPene.
De Sarro GB; De Sarro A
Neuropharmacology; 1993 Jan; 32(1):51-8. PubMed ID: 8094234
[TBL] [Abstract][Full Text] [Related]
11. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil.
Löscher W; Hönack D
Br J Pharmacol; 1994 Dec; 113(4):1349-57. PubMed ID: 7889291
[TBL] [Abstract][Full Text] [Related]
12. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice.
De Sarro G; Ongini E; Bertorelli R; Aguglia U; De Sarro A
Eur J Pharmacol; 1994 Sep; 262(1-2):11-9. PubMed ID: 7529182
[TBL] [Abstract][Full Text] [Related]
13. LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy.
Potschka H; Löscher W; Wlaź P; Behl B; Hofmann HP; Treiber HJ; Szabo L
Br J Pharmacol; 1998 Nov; 125(6):1258-66. PubMed ID: 9863655
[TBL] [Abstract][Full Text] [Related]
14. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy.
Löscher W; Rundfeldt C; Hönack D
Eur J Neurosci; 1993 Nov; 5(11):1545-50. PubMed ID: 7904524
[TBL] [Abstract][Full Text] [Related]
15. The effect of the non-NMDA receptor antagonist GYKI 52466 and NBQX and the competitive NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures.
Dürmüller N; Craggs M; Meldrum BS
Epilepsy Res; 1994 Feb; 17(2):167-74. PubMed ID: 8194512
[TBL] [Abstract][Full Text] [Related]
16. Contrasting effects of D- and L-(E)-4-(3-phosphono-2-propenyl)piperazine-2-carboxylic acid as anticonvulsants and as inhibitors of potassium-evoked increases in hippocampal extracellular glutamate and aspartate levels in freely moving rats.
Millan MH; Chapman AG; Meldrum BS
J Neurochem; 1994 Jan; 62(1):217-22. PubMed ID: 7903351
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of non-NMDA receptors inhibits handling-induced, strychnine-potentiated convulsions.
McAllister KH
Eur J Pharmacol; 1993 Feb; 231(2):309-12. PubMed ID: 8384115
[TBL] [Abstract][Full Text] [Related]
18. Effects of 7-nitroindazole, NG-nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions.
Eblen F; Löschmann PA; Wüllner U; Turski L; Klockgether T
Eur J Pharmacol; 1996 Mar; 299(1-3):9-16. PubMed ID: 8901001
[TBL] [Abstract][Full Text] [Related]
19. Anticonvulsant activity of competitive antagonists of NMDA receptor in genetically epilepsy-prone rats.
De Sarro G; De Sarro A
Eur J Pharmacol; 1992 May; 215(2-3):221-9. PubMed ID: 1396987
[TBL] [Abstract][Full Text] [Related]
20. Acute and chronic anticonvulsant effects of D(-)CPPene in genetically epilepsy-prone rats.
Smith SE; Chapman AG
Epilepsy Res; 1993 Jul; 15(3):193-9. PubMed ID: 8223415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
